Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Luis Teixeira

Université Paris Cité

France

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

60%

Pharmacology

30%

Oncology

50%

Adjuvant Therapy

40%

Targeted Therapy

30%

Drug Repositioning

30%

Tumor Immunology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Article Link

Year:

2025

A Life course approach to investigate breast cancer and migration in the greater Paris area: the SENOVIE study protocol

Article Link

Year:

2025

Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.

Article Link

Year:

2025

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Article Link

Year:

2025

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Article Link

Year:

2024

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

Article Link

Year:

2024

Dynamic Projection of Medication Nonpersistence and Nonadherence Among Patients With Early Breast Cancer.

Article Link

Year:

2024

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Article Link

Year:

2024

Access to oncology care in Mali: a qualitative study on breast cancer.

Article Link

Year:

2024

Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugués dans le cancer du sein : avis d’expert

Article Link

Year:

2023

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Article Link

Year:

2023

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Article Link

Year:

2022

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

Article Link

Year:

2022

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Article Link

Year:

2022

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

Article Link

Year:

2022

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

Article Link

Year:

2022

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Article Link

Year:

2022

SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

Article Link

Year:

2022

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Article Link

Year:

2021

Ten-year outcomes of hypofractionated postmastectomy radiation therapy of 26 Gy in 6 fractions

Article Link

Year:

2021

Collaborators11

Daniel Rea

Professor of Medical Oncology

University of Birmingham

UNITED KINGDOM

Iain Macpherson

Professor of Breast Oncology

UNITED KINGDOM

Judith Balmaña

Head

Hospital Universitari Vall d'Hebron

SPAIN

Hope Rugo

Professor of Medicine

UNITED STATES

Andrea Eisen

McMaster University

CANADA

Hervé Bischoff

Institut de Cancérologie Strasbourg

FRANCE

seamus o'reilly

prof

Cork University Hospital

IRELAND

Virginie Westeel

Université de Franche-Comté

FRANCE

Anne-Sophie HAMY

Institut Curie

FRANCE

Isabelle Demeestere

Université libre de Bruxelles

BELGIUM

Rafal Tarnawski

Head of Department

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

How do I reach out?

Meet Kite AI